Each patient treated with BTK inhibitors, including ibrutinib, in Saskatchewan undergoes a detailed medical history review and a focused CV risk examination, including an electrocardiogram (ECG) and blood pressure measurement, to identify common risk factors such as AF and hypertension. Here, BTK is linked to atrial fibrillation.